Quick Answer
Vivos Therapeutics, Inc. reported Diluted EPS of $2.22 per share (loss) for fiscal year 2024.
Vivos Therapeutics, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2024 | -$2.22 | +80.1% |
| 2023 | -$11.14 | +57.0% |
| 2022 | -$25.90 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.49 | -22.5% | +10.9% |
| June 30, 2025 | -$0.55 | +8.3% | -22.2% |
| March 31, 2025 | -$0.45 | +72.4% | -12.5% |
| September 30, 2024 | -$0.40 | +77.1% | +33.3% |
| June 30, 2024 | -$0.60 | +87.0% | +63.2% |
| March 31, 2024 | -$1.63 | +5.2% | +6.9% |
| September 30, 2023 | -$1.75 | +72.7% | +62.1% |
| June 30, 2023 | -$4.62 | -1300.0% | -168.6% |
- Vivos Therapeutics, Inc. showed an increase of +80.1% in Diluted EPS compared to the prior fiscal year.
- Over the 2022–2024 period, Vivos Therapeutics, Inc.’s diluted eps has grown by 91.4% (from $25.90 per share (loss) to $2.22 per share (loss)).
- The most recent figure is from Vivos Therapeutics, Inc.’s fiscal year 2024 report (Form 10-K), filed with the SEC on March 31, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: